Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
This article details a significant $2.75 billion deal where Eli Lilly will partner with Insilico to bring AI-discovered drugs to market. For financial advisors, this highlights the increasing commercialization and market value of AI in the pharmaceutical sector, signaling a growing trend of AI adoption impacting investment opportunities and industry analysis.
Read full article at cnbc-techWant the full daily Briefing?
30 stories like this every day, with Action Required call-outs and direct lines to ask Aria — finsay's AI compliance assistant.
Try free for 14 daysRelated stories
- Stalking victim sues OpenAI, claims ChatGPT fueled her abuser’s delusions and ignored her warnings
This lawsuit against OpenAI, alleging its ChatGPT tool was misused for stalking despite ignored warnings, underscores significant ethical an…
- This Startup Wants You to Pay Up to Talk With AI Versions of Human Experts
Onix is launching a platform where AI versions of human experts, like health and wellness influencers, provide advice and potentially hawk p…
- Meta’s New AI Asked for My Raw Health Data—and Gave Me Terrible Advice
This article highlights the privacy risks and limitations of AI models like Meta's Muse Spark, which offered to analyze sensitive health dat…